Market reactionShares rose 11% on Nov 4.
Prime Medicine develops prime editing gene therapies; its most advanced, PM359 for chronic granulomatous disease (a rare immune disorder), is not approved, and two liver programs entered the clinic in 2026.
Prime Medicine plans a BLA in the first half of 2027 for PM359, prime-edited stem cells for p47phox chronic granulomatous disease. The filing would rest on positive data from its first two patients, and FDA has not publicly agreed an approval path. The company is shifting to liver programs: PM577a for Wilson disease dosed its first patient in October, and FDA cleared PM647 for alpha-1 antitrypsin deficiency in September. Cash of $108.8 million lasts into 2027, and the 10-Q reports going-concern doubt.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: PM359 BLA path agreed with FDA
Does Prime Medicine submit a PM359 BLA with FDA agreement on the evidence needed?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Prime Medicine plans a 2027 PM359 BLA while cash is guided only into 2027
PM359 prime editing therapy for a fatal pediatric immune disease races a BLA filing against a going-concern clock, with survival contingent on capital raising
PM359's NEJM-published CGD data sets up a BLA attempt, but FDA alignment on an accelerated approval path remains the decisive gate
Prime Medicine's PM359 carries NEJM-validated CGD data toward a potential accelerated approval BLA, contingent on FDA alignment confirming the two-patient dataset is sufficient
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Other cancers, Lung and respiratory diseases, Autoimmune and inflammatory diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.